Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Regeneron Pharmaceuticals has entered a strategic licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for the clinical development and commercialization of HS-20094, a dual ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...